IC
VIR icon

Ikarian Capital’s Vir Biotechnology VIR Stock Holding History

Ikarian Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-720,300
Closed -$5.29M – 220
2024
Q4 		$5.29M Buy
+720,300
New +$5.68M 0.72% 39

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Ikarian Capital's VIR Position: Q1 2026 in Review

Ikarian Capital reduced its Vir Biotechnology (VIR) stake by 49% in Q1 2026, selling an estimated $2.25M and leaving 293,258 shares worth $2.63M. The position accounts for 0.21% of the portfolio, ranked #85.

Ikarian Capital first reported a position in VIR in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.92M in Q1 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Ikarian Capital held 293,258 shares of Vir Biotechnology worth $2.63M as of Q1 2026.
  • Ikarian Capital sold 282,454 Vir Biotechnology shares in Q1 2026, an estimated $2.25M.
  • Vir Biotechnology made up 0.21% of Ikarian Capital's portfolio in Q1 2026, its #85 holding.
  • Ikarian Capital first reported a position in Vir Biotechnology in Q4 2024 and has held it in 6 quarters since.
  • Ikarian Capital's Vir Biotechnology position peaked at $6.92M in Q1 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.